EntreMed Reports Positive Results for Its Cancer Treatment
The biopharmaceutical company says its treatment for blood cancer has shown positive results.
Biopharmaceutical company
EntreMed
(ENMD)
said its new blood cancer treatment has shown positive preclinical results.
The treatment, a derivative of thalidomide, showed sustained tumor regression in multiple myeloma, a blood cancer that causes bone loss. The company said the treatment also showed less toxicity and greater anti-tumor activity than thaliodomide, now commonly used in experimental multiple myeloma treatment.
The company previously licensed its thaliodomide treatment to Celgene Corporation and sold its future royalties for $24.3 million to Royalty-Pharma. The thaliodomide derivatives were excluded from that agreement.
Shares of ENMD closed at $7.49 Friday on the
Nasdaq
.
